O	0	6	BREATH
O	6	7	:
B-intervention	8	11	Web
I-intervention	11	12	-
I-intervention	12	17	Based
I-intervention	18	22	Self
I-intervention	22	23	-
I-intervention	23	33	Management
O	34	37	for
B-condition	38	51	Psychological
I-condition	52	62	Adjustment
O	63	68	After
O	69	76	Primary
O	77	83	Breast
O	84	90	Cancer
O	90	91	-
O	91	92	-
O	92	99	Results
O	100	102	of
O	103	104	a
O	105	116	Multicenter
O	117	127	Randomized
O	128	138	Controlled
O	139	144	Trial
O	144	145	.

O	146	151	Early
O	152	158	breast
O	159	165	cancer
O	166	175	survivors
O	176	177	(
O	177	181	BCSs
O	181	182	)
O	183	189	report
O	190	194	high
O	195	200	unmet
O	201	205	care
O	206	211	needs
O	211	212	,
O	213	216	and
O	217	223	easily
O	224	234	accessible
O	235	239	care
O	240	242	is
O	243	246	not
O	247	256	routinely
O	257	266	available
O	267	270	for
O	271	275	this
O	276	283	growing
O	284	294	population
O	294	295	.

O	296	299	The
O	300	306	Breast
O	307	313	Cancer
O	314	315	E
O	315	316	-
O	316	322	Health
O	323	324	(
O	324	330	BREATH
O	330	331	)
O	332	337	trial
O	338	340	is
O	341	342	a
O	343	346	Web
O	346	347	-
O	347	352	based
O	353	357	self
O	357	358	-
O	358	368	management
O	369	381	intervention
O	382	384	to
O	385	392	support
O	393	396	the
O	397	410	psychological
O	411	421	adjustment
O	422	424	of
O	425	430	women
O	431	436	after
O	437	444	primary
O	445	454	treatment
O	454	455	,
O	456	458	by
O	459	467	reducing
O	468	476	distress
O	477	480	and
O	481	490	improving
O	491	502	empowerment
O	502	503	.

O	504	508	This
O	509	520	multicenter
O	520	521	,
O	522	532	randomized
O	532	533	,
O	534	544	controlled
O	544	545	,
O	546	554	parallel
O	554	555	-
O	555	560	group
O	561	566	trial
O	567	576	evaluated
O	577	584	whether
O	585	589	care
O	590	592	as
O	593	598	usual
O	599	600	(
O	600	603	CAU
O	603	604	)
O	605	609	plus
O	610	616	BREATH
O	617	619	is
O	620	628	superior
O	629	631	to
O	632	635	CAU
O	636	641	alone
O	641	642	.

O	643	649	BREATH
O	650	652	is
O	653	662	delivered
O	663	665	in
O	666	673	sixteen
O	674	679	fully
O	680	689	automated
O	690	696	weekly
O	697	704	modules
O	705	713	covering
O	714	719	early
O	720	732	survivorship
O	733	739	issues
O	739	740	.

O	741	744	Two
O	745	747	to
O	748	749	4
O	750	756	months
O	757	761	post
O	761	762	-
O	762	771	treatment
O	771	772	,
O	773	777	BCSs
O	778	782	were
O	783	791	randomly
O	792	800	assigned
O	801	803	to
O	804	811	receive
O	812	815	CAU
O	816	817	+
O	818	824	BREATH
O	825	826	(
O	826	827	n
O	828	829	=
B-intervention-participants	830	832	70
O	832	833	)
O	834	836	or
B-control	837	840	CAU
I-control	841	846	alone
O	847	848	(
O	848	849	n
O	850	851	=
B-control-participants	852	854	80
O	854	855	)
O	856	861	using
O	862	863	a
O	864	874	stratified
O	875	880	block
O	881	887	design
O	888	889	(
O	889	894	ratio
O	895	896	1
O	896	897	:
O	897	898	1
O	898	899	)
O	899	900	.

O	901	908	Primary
O	909	917	outcomes
O	918	922	were
B-outcome-Measure	923	931	distress
I-outcome-Measure	932	933	(
I-outcome-Measure	933	940	Symptom
I-outcome-Measure	941	950	Checklist
I-outcome-Measure	950	951	-
I-outcome-Measure	951	953	90
I-outcome-Measure	953	954	)
I-outcome-Measure	955	958	and
I-outcome-Measure	959	970	empowerment
I-outcome-Measure	971	972	(
I-outcome-Measure	972	978	Cancer
I-outcome-Measure	979	990	Empowerment
I-outcome-Measure	991	1004	Questionnaire
I-outcome-Measure	1004	1005	)
O	1005	1006	,
O	1007	1015	assessed
O	1016	1022	before
O	1023	1029	random
O	1030	1040	assignment
O	1041	1042	(
O	1042	1050	baseline
O	1050	1051	,
O	1052	1054	T0
O	1054	1055	)
O	1056	1059	and
O	1060	1065	after
O	1066	1067	4
O	1068	1069	(
O	1069	1071	T1
O	1071	1072	)
O	1072	1073	,
O	1074	1075	6
O	1076	1077	(
O	1077	1079	T2
O	1079	1080	)
O	1080	1081	,
O	1082	1085	and
O	1086	1088	10
O	1089	1095	months
O	1096	1097	(
O	1097	1099	T3
O	1099	1100	)
O	1101	1103	of
O	1104	1110	follow
O	1110	1111	-
O	1111	1113	up
O	1113	1114	.

O	1115	1126	Statistical
O	1127	1128	(
O	1128	1136	analysis
O	1137	1139	of
O	1140	1150	covariance
O	1150	1151	)
O	1152	1155	and
O	1156	1164	clinical
O	1165	1172	effects
O	1173	1174	(
O	1174	1182	reliable
O	1183	1189	change
O	1190	1195	index
O	1195	1196	)
O	1197	1201	were
O	1202	1208	tested
O	1209	1211	in
O	1212	1214	an
O	1215	1224	intention
O	1224	1225	-
O	1225	1227	to
O	1227	1228	-
O	1228	1233	treat
O	1234	1242	analysis
O	1243	1244	(
O	1244	1246	T0
O	1247	1249	to
O	1250	1252	T1
O	1252	1253	)
O	1253	1254	.

O	1255	1261	Follow
O	1261	1262	-
O	1262	1264	up
O	1265	1272	effects
O	1273	1274	(
O	1274	1276	T0
O	1277	1279	to
O	1280	1282	T3
O	1282	1283	)
O	1284	1288	were
O	1289	1297	assessed
O	1298	1300	in
O	1301	1311	assessment
O	1312	1322	completers
O	1322	1323	.

O	1324	1327	CAU
O	1328	1329	+
O	1330	1336	BREATH
O	1337	1349	participants
O	1350	1358	reported
O	1359	1372	significantly
B-outcome	1373	1377	less
I-outcome	1378	1386	distress
O	1387	1391	than
O	1392	1395	CAU
O	1395	1396	-
O	1396	1401	alone
O	1402	1414	participants
O	1415	1416	(
O	1416	1417	-
O	1417	1418	7
O	1418	1419	.
O	1419	1421	79
O	1421	1422	;
O	1423	1425	95
O	1425	1426	%
O	1427	1429	CI
O	1429	1430	,
O	1431	1432	-
O	1432	1434	14
O	1434	1435	.
O	1435	1437	31
O	1438	1440	to
O	1441	1442	-
O	1442	1443	1
O	1443	1444	.
O	1444	1446	27
O	1446	1447	;
O	1448	1449	P
O	1450	1451	=
O	1452	1453	.
O	1453	1455	02
O	1455	1456	)
O	1457	1461	with
O	1462	1463	a
O	1464	1469	small
O	1469	1470	-
O	1470	1472	to
O	1472	1473	-
O	1473	1479	medium
O	1480	1486	effect
O	1487	1491	size
O	1492	1493	(
O	1493	1494	d
O	1495	1496	=
O	1497	1498	0
O	1498	1499	.
O	1499	1501	33
O	1501	1502	)
O	1502	1503	,
O	1504	1507	but
B-outcome	1508	1519	empowerment
O	1520	1523	was
O	1524	1527	not
O	1528	1536	affected
O	1537	1538	(
O	1538	1539	-
O	1539	1540	1
O	1540	1541	.
O	1541	1543	71
O	1543	1544	;
O	1545	1547	95
O	1547	1548	%
O	1549	1551	CI
O	1551	1552	,
O	1553	1554	5
O	1554	1555	.
O	1555	1557	20
O	1558	1560	to
O	1561	1562	-
O	1562	1563	1
O	1563	1564	.
O	1564	1566	79
O	1566	1567	;
O	1568	1569	P
O	1570	1571	=
O	1572	1573	.
O	1573	1575	34
O	1575	1576	)
O	1576	1577	.

O	1578	1582	More
O	1583	1586	CAU
O	1587	1588	+
O	1589	1595	BREATH
O	1596	1608	participants
O	1609	1610	(
B-iv-bin-abs	1610	1612	39
O	1613	1615	of
B-intervention-participants	1616	1618	70
O	1619	1620	[
B-iv-bin-percent	1620	1622	56
I-iv-bin-percent	1622	1623	%
O	1623	1624	]
O	1624	1625	;
O	1626	1628	95
O	1628	1629	%
O	1630	1632	CI
O	1632	1633	,
O	1634	1636	44
O	1636	1637	.
O	1637	1638	1
O	1639	1641	to
O	1642	1644	66
O	1644	1645	.
O	1645	1646	8
O	1646	1647	)
O	1648	1652	than
O	1653	1656	CAU
O	1656	1657	-
O	1657	1662	alone
O	1663	1675	participants
O	1676	1677	(
B-cv-bin-abs	1677	1679	32
O	1680	1682	of
B-control-participants	1683	1685	80
O	1686	1687	[
B-cv-bin-percent	1687	1689	40
I-cv-bin-percent	1689	1690	%
O	1690	1691	]
O	1691	1692	;
O	1693	1695	95
O	1695	1696	%
O	1697	1699	CI
O	1699	1700	,
O	1701	1703	30
O	1703	1704	.
O	1704	1705	0
O	1706	1708	to
O	1709	1711	51
O	1711	1712	.
O	1712	1713	0
O	1713	1714	)
O	1715	1721	showed
B-outcome	1722	1732	clinically
I-outcome	1733	1744	significant
I-outcome	1745	1756	improvement
O	1757	1758	(
O	1758	1759	P
O	1760	1761	=
O	1762	1763	.
O	1763	1765	03
O	1765	1766	)
O	1766	1767	.

O	1768	1772	This
O	1773	1781	clinical
O	1782	1788	effect
O	1789	1792	was
O	1793	1797	most
O	1798	1807	prominent
O	1808	1810	in
O	1811	1814	low
O	1814	1815	-
O	1815	1823	distress
O	1824	1828	BCSs
O	1828	1829	.

O	1830	1839	Secondary
O	1840	1848	outcomes
O	1849	1858	confirmed
O	1859	1866	primary
O	1867	1875	outcomes
O	1875	1876	.

O	1877	1882	There
O	1883	1887	were
O	1888	1890	no
O	1891	1898	between
O	1898	1899	-
O	1899	1904	group
O	1905	1916	differences
O	1917	1919	in
O	1920	1927	primary
O	1928	1936	outcomes
O	1937	1943	during
O	1944	1950	follow
O	1950	1951	-
O	1951	1953	up
O	1953	1954	.

O	1955	1961	Access
O	1962	1964	to
O	1965	1971	BREATH
O	1972	1979	reduced
O	1980	1988	distress
O	1989	1994	among
O	1995	1999	BCSs
O	1999	2000	,
O	2001	2004	but
O	2005	2009	this
O	2010	2016	effect
O	2017	2020	was
O	2021	2024	not
O	2025	2034	sustained
O	2035	2041	during
O	2042	2048	follow
O	2048	2049	-
O	2049	2051	up
O	2051	2052	.
